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Abstract: Managing pain from chronic conditions, such as, but not limited to, osteoarthritis and rheumatoid arthritis, 
requires the clinician to balance the need for effective analgesia against safety risks associated with analgesic agents. 
Osteoarthritis and rheumatoid arthritis pain is incompletely understood but involves both nociceptive and non-nociceptive 
mechanisms, including neuropathic mechanisms. Prevailing guidelines for arthritis-related pain do not differentiate 
between nociceptive and non-nociceptive pain, sometimes leading to recommendations that do not fully address the nature 
of pain. NSAIDs are effective in treating the nociceptive arthritis-related pain. However, safety concerns of NSAIDs may 
cause clinicians to undertreat arthritis-related pain. In this context, combination therapy may be more appropriate to 
manage the different pain mechanisms involved. A panel convened in November 2010 found that among the currently 
recommended analgesic products for arthritis-related pain, fixed-low-dose combination products hold promise for pain 
control because such products allow lower doses of individual agents resulting in decreased toxicity and acceptable 
efficacy due to synergy between the individual drugs. Better evidence and recommendations are required to improve 
treatment of chronic arthritis-related pain. 
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INTRODUCTION 
 Osteoarthritis (OA) and rheumatoid arthritis (RA) cause 
chronic pain, which may involve nociceptive as well as non-
nociceptive components, including neuropathic components, 
due to peripheral inflammation and central sensitization [1, 
2]. Despite our modern wealth of analgesic options, 
managing moderate to severe chronic pain remains clinically 
challenging for several reasons. These reasons include: the 
heterogeneity of the patient populations, the progressive 
nature of the disorders, the multiple pain mechanisms 
involved, the presence of comorbidities and co-medication in 
predominantly frail and elderly patients, and the efficacy and 
safety profiles of available pain medications [3]. OA and RA 
patients frequently require lifelong pain management 
regimens, ruling out those pharmacological therapies 
effective for acute pain but inappropriate for long-term use.  
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In fact, many analgesic agents carry a substantial degree of 
risk, which has created barriers in pain management, in that 
clinicians may undertreat pain in an effort to enhance patient 
safety and minimize potential side effects [4]. Since chronic 
pain itself is associated with considerable mortality [5-7], 
public health organizations today view effective analgesia as 
a fundamental human right [8-10]. Not treating pain is not 
an option. 
ISSUES IN OA PAIN 
 OA is a prevalent disorder characterized by the 
progressive destruction of articular cartilage associated with 
subchondral bone remodeling, formation of osteophytes, and 
secondary inflammation of synovial membranes [11, 12]. Its 
principal symptom is pain, which is mediated by a number of 
factors. Amongst others, innervation and vascularisation of 
the articular cartilage may be involved, and compressive 
forces and hypoxia may stimulate these new nerves, causing 
pain even after inflammation has subsided [13]. Innervation 
of the joint tissue and angiogenesis have been described as 
main pathophysiological pathways causing the deep joint  
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pain described by some OA patients [13, 14]. The pain of 
OA includes both nociceptive and non-nociceptive 
components and is associated with abnormally excitable pain 
pathways in the peripheral and central nervous systems [15, 
16]. Quantitative sensory testing in OA patients reveals that 
OA patients have lower thresholds for mechanical and 
thermal pain than healthy controls [1, 17] and increased 
sensitivity to pressure, ischemia, and innocuous stimuli [18]. 
OA patients were shown to have lower pain thresholds than 
control subjects at the forehead, a non-painful area of the 
body unaffected by OA [19]. Such findings suggest that OA 
pain is also centrally mediated [20]. Functional magnetic 
resonance imaging (fMRI) studies have identified several 
brain regions involved in OA pain processing, indicating the 
complexity of OA pain mechanisms [21]. 
 OA is prevalent in the global geriatric population [22]. In 
general, long-term analgesia is challenging in the elderly, a 
challenge not always addressed in the literature or 
guidelines. Since few randomized clinical trials enroll 
geriatric patients, and even fewer enroll elderly patients of 
diverse races and ethnicities, there are limited data available 
in the literature for this particular population. Furthermore, 
elderly patients often have comorbidities, which may 
increase the risk of drug-drug interactions and limit the range 
of drugs to be used. Age-associated differences in drug 
sensitivities should be considered when treating older 
patients [23], although the heterogeneous nature of the 
geriatric OA population precludes clear-cut uniform 
guidelines for all elderly OA patients. Opioids have been 
shown to be effective in the elderly, but must be used under 
close clinical supervision [24]. 
ISSUES IN RA PAIN 
 RA is a progressive disorder characterized by periods 
when the disease is active punctuated by periods of 
remission. Patients may suffer persistent or intermittent pain, 
which can be moderate to severe. RA is an inflammatory 
disease that causes destruction of cartilage and underlying 
bone. Since the joint capsule and synovium are densely 
innervated, pain can be intense and may be triggered by even 
gentle stimulation or slight movement of the affected joint 
[25]. The local inflammatory response is mediated by the 
immune system along with resident non-immune cells 
(synovial fibroblasts). Local inflammation triggers the 
release of multiple factors, including pro-inflammatory 
cytokines, histamines, bradykinins, serotonin, prostaglandin 
E2, and others. Peripheral nociceptors become sensitized 
owing to the altered cytokine balance. Cellular cascades 
initiate central sensitization [25]. RA patients have lower 
thresholds for pressure pain than healthy controls, further 
suggesting altered central pain processing [26, 27]. 
Enhanced cortical responses to noxious stimuli in RA 
patients suggest cellular changes affecting pain-processing 
signals [28]. Peripheral sensitization, central sensitization, 
and inflammation interact in RA patients in ways not yet 
completely understood. 
MEETING DETAILS 
 In November 2010, a panel convened in Paris, France, to 
discuss the management of moderate to severe pain from  
 
different etiologies with special emphasis on NSAIDs,  
paracetamol and fixed-dose combination products. 
Following presentations by several authors of this article, all 
authors discussed and reviewed pain management and 
available guidelines/recommendations based on their own 
clinical experiences. Their final consensus on pain 
management for the indications osteoarthritis and 
rheumatoid arthritis is summarized in this publication and 
incorporates additional articles which were deemed relevant 
in discussions during the draft stages. 
CURRENT ANALGESICS USED TO TREAT 
ARTHRITIS-RELATED PAIN 
 The focus of rheumatology is the best possible patient 
care and management of disease-related pain and impact on 
the patient by understanding the underlying 
pathophysiological aspects of this inflammatory disease 
process. Greater understanding of pain mechanisms and 
growing appreciation for pain control have, however, caused 
rheumatologists to consider new approaches in pain 
management. Whereas central pain mechanisms are 
increasingly addressed in the pharmacological therapy for 
fibromyalgia patients, it is less clear how to manage the 
centralized pain processes in OA and RA patient 
populations. Therefore, it has been proposed that clinicians 
change the concept of pain control in arthritis-related pain to 
one of “pain-modifying analgesic drugs” [29]. The following 
drugs are the main categories of pharmacological agents 
used for pain control in OA and RA patients. It should be 
noted that all treatment options may be combined with 
nonpharmacological approaches. 
Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) 
 Both selective and nonselective cyclooxygenase (COX) 
inhibitors have antipyretic, anti-inflammatory and analgesic 
effects and are widely used in treating many painful 
conditions, including rheumatic diseases [30]. NSAIDs are 
effective and widely available in over-the-counter 
formulations and in prescription products. Examples include 
ibuprofen, naproxen, diclofenac, and celecoxib. NSAIDs are 
frequently used without considering the relative 
contraindications since most NSAIDs are sold over the 
counter [31]. Conventional NSAIDs are associated with 
gastrointestinal (GI) side effects [32]. Estimates of the 
number of deaths from NSAID-related gastrointestinal 
bleeding vary widely and figures of approx. 3500 to 16.500 
per year are quoted for the US in a recent FDA report [33]. 
Both conventional NSAIDs and COX-2 inhibitors are 
associated with increased cardiovascular risk [34-37]. 
NSAIDs may increase blood pressure [38], particularly in 
hypertensive patients [39]. Of all NSAIDs, naproxen seems 
to pose the least cardiovascular risk [37, 40], although 
naproxen is associated with the same risk for myocardial 
infarction as other NSAIDs [35]. 
 Contrary to some clinical assumptions, gastrointestinal 
risk is present at first dose with a non-selective NSAID, and 
co-therapy with a proton pump inhibitor (PPI) does not 
guarantee complete protection [41]. COX-2 selective 
NSAIDs, especially in combination with a PPI, provide 
prophylaxis against NSAID gastropathy [42]. The incidence  
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and severity of gastrointestinal adverse events associated 
with NSAID therapy increases with advancing age, limiting  
their clinical utility in the geriatric population, particularly in 
concomitant use with low-dose aspirin, taken by many 
elderly patients for cardioprotection [43, 44]. NSAIDs 
should be used at the lowest effective dose for the shortest 
possible period of time in chronic pain populations. In 
addition to the above mentioned risks, NSAIDS may interact 
with many other medicinal products [45-48] and special 
caution and close monitoring is recommended in particular 
for elderly patients and patients with a history or symptoms 
indicative of gastrointestinal disorders, patients with renal, 
cardiac or hepatic impairment, a history of hypertension, 
asthma, seasonal allergic rhinitis, systemic lupus 
erythematosus (SLE) and mixed connective tissue disorders 
[45-48]. Very rarely serious skin reactions, some of them 
fatal, including exfoliative dermatitis, Stevens-Johnson 
syndrome and toxic epidermal necrolysis, have been reported 
in association with the use of NSAIDs [45-48]. Accumulated 
toxicity and the above-mentioned potential risks are the main 
reasons that there are no suitable agents for long-term 
treatment [49, 50]. 
Paracetamol 
 The antipyretic and analgesic effects of paracetamol 
(acetaminophen or APAP) have been known since the late 
19th century. It is often considered a first-line approach to 
pain management [51], although there is a risk of 
hepatoxicity at high doses. Even at recommended therapeutic 
doses of paracetamol up to 4 g/d, otherwise healthy adults 
can exhibit abnormally high levels of aminotransferase [52]. 
Although high doses of paracetamol are known to be toxic, 
such supratherapeutic doses of paracetamol are sometimes 
prescribed and dispensed [53]. Paracetamol is widely 
available over the counter and in prescription products and 
many combination products contain paracetamol, but 
patients may equate the drug’s familiarity with safety and 
wrongly consider it more or less harmless. Twelve percent of 
patients believe that it is not possible to ingest a toxic dose of 
paracetamol [54]. Furthermore, even patients who 
understand the potential toxicity of paracetamol may be 
unaware that it is found in a wide range of over-the-counter 
products from cold medicines to headache remedies. Patients 
taking such over-the-counter products may be unaware of 
“hidden paracetamol” in such products and unaware of the 
risk of high cumulative doses [54]. 
 Paracetamol was shown in one study to significantly 
increase blood pressure in ambulatory patients with coronary 
artery disease [55]. The frequency of use of paracetamol has 
been independently associated with a moderately increased 
risk of hypertension in men [56]. There is some evidence in 
the literature to suggest that paracetamol may have an anti-
inflammatory effect in patients with OA of the knee [57]. 
Although earlier reports describe paracetamol as having no 
or minimal anti-inflammatory effects, increasing reports 
suggest, that in addition, it may have a beneficial effect on 
inflammation distinct from the anti-inflammatory effects of 
NSAIDs [58]. Further study in that field is warranted. 
 
 
 
Tramadol 
 Tramadol is considered a weak opioid on the WHO pain 
ladder [59]. Due to its differences to other opioids, it will be 
discussed separately here. Tramadol’s analgesic effect 
derives from a combination of an agonist action at mu-opioid 
receptors (low affinity of parent drug, much higher affinity 
of its M1, O-desmethyl, metabolite) and inhibition of 
neuronal reuptake of serotonin (5-HT, 5-hydroxytryptamine) 
and norepinephrine [60]. Tramadol has been shown to 
decrease pain intensity in OA patients and to improve 
function; active-controlled studies show that tramadol 
provides analgesic benefits similar to diclofenac and superior 
to paracetamol [61]. Extended-release formulations of 
tramadol have been shown effective in treating chronic pain 
associated with OA as well as offering improvement in pain-
related sleep disorders [62]. 
 Tramadol may be associated with a risk of dependence or 
abuse; the prevalence of abuse/dependence over a 12-month 
period in patients with chronic non-cancer pain was, 
however, equivalent for tramadol and NSAIDs, and 
significantly less than for hydrocodone [63]. In patients 
prone to convulsive disorders, the risk of convulsions may 
increase if tramadol is taken concomitantly with medication 
that lowers the seizure threshold. Some cases of serotonergic 
syndrome have been reported with the therapeutic use of 
tramadol in combination with other serotonergic agents such 
as selective serotonin re-uptake inhibitors (SSRIs) [64]. 
Recommended dosing should not exceed 400 mg/d, and 
should be reduced or closely supervised in geriatric patients 
( 75 years) and those with cirrhosis or renal dysfunction 
[30]. Tramadol has no known anti-inflammatory effects. 
Opioids 
 Since 1990, opioids have been recommended in the setting 
of long-term non-cancer pain syndromes [65]. Growing public 
health concerns about prescription opioid abuse and particularly 
about the diversion of prescribed products to the street have 
focused greater scrutiny on opioid prescribing practices [66-68]. 
Another concern regarding opioids is the perceived high danger 
of addiction. Various studies have, however, demonstrated that 
opioid analgesics for chronic pain conditions are not associated 
with a major risk for developing dependence [69]. Concern 
about opioid diversion and misuse has led to the development of 
so-called abuse-deterrent formulations, as a means for suppor-
ting opioid access while limiting abuse and its consequences 
[70, 71]. 
 Opioids are effective in treating chronic pain [72] but are 
associated with side effects, including nausea, constipation, 
and somnolence. Opioids may be appropriate for use in the 
elderly under close supervision, sometimes at reduced doses 
[24], or as low-dose transdermal treatment, e.g., 
buprenorphine [73, 74]. Recently, tapentadol extended-
release has shown promise in the treatment of moderate to 
severe chronic pain related to OA [75, 76]. 
 In summary, clinicians may be cautious in prescribing 
opioids to treat OA or RA for clinical, legal, or public health 
reasons [77]. 
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Tricyclic Antidepressants 
 Amongst other mechanisms, tricyclic antidepressants 
(TCAs, e.g. amitriptyline, dothiepin, and imipramine) inhibit 
serotonin and norepinephrine reuptake and neuronal sodium 
channels [78]. Various tricyclic TCAs differ with regard to 
their antinociceptive effects, and the non-serotoninergic 
properties of TCAs are believed to substantially contribute to 
these differences [79]. 
 TCAs provide significant pain relief in RA patients 
versus placebo [80-83]. The use of TCAs in arthritis has 
found such a wide distribution that it has been proposed that 
these agents along with anticonvulsants should be described 
as “pain-modifying drugs” [29]. TCAs offer arthritis patients 
an analgesic benefit apart from their antidepressive effects. It 
has been speculated that at least part of this benefit relates to 
improvement of fatigue and sleep disorders [84]. TCAs are 
associated with certain adverse events, which include 
sedation, dizziness, blurred vision, constipation, and dry 
mouth, which can be treatment limiting. Dry mouth can be of 
particular concern for RA patients with secondary Sjögren’s 
syndrome [20]. Cardiac toxicity is a concern with TCAs, and 
the NeuPSIG guidelines (Neuropathic Pain Special Interest 
Group) recommend prescribing TCAs with caution in 
patients with ischemic cardiac disease or ventricular 
conduction abnormalities [85]. Some TCAs, e.g. 
amitriptyline, are listed on the recently revised Beers list 
(American Geriatrics Society) of potentially inappropriate 
medication use in older adults with a strong recommendation 
to avoid using them because they are highly anticholinergic, 
sedating, and cause orthostatic hypotension [86]. Since 
arthritis primarily occurs in the elderly, TCAs are usually not 
suitable. 
Anticonvulsants 
 Anticonvulsants, e.g., gabapentin and pregabalin, bind to 
the alpha2delta subunit of calcium channels and modulate 
the release of neurotransmitters, including glutamate, 
noradrenalin, serotonin, and substance P. As such, these 
agents may provide analgesic relief for patients with central 
sensitization. However, the mechanisms of action of these 
drugs are still poorly understood [87]. While known to be 
effective analgesics for fibromyalgia, these agents have not 
been studied in RA and OA populations. Pregabalin was 
shown in a preclinical study to be effective in reducing pain 
in an OA model [88]. Both agents are associated with 
adverse events. In a meta-analysis of pregabalin in adult 
acute and chronic pain patients, 18% to 28% of participants 
discontinued the study owing to adverse effects (n=19 
studies with 7,003 patients) [89]. 
Serotonin Norepinephrine Reuptake Inhibitors  
 Serotonin norepinephrine reuptake inhibitors (SNRIs), 
inhibit serotonin and/or norepinephrine reuptake selectively, 
e.g., duloxetine and milnacipran. Overall, SNRIs are better 
tolerated than TCAs but may be less effective analgesics; 
they are not recommended as first-line drugs for analgesia in  
 
 
 
RA patients, although they may be useful to manage sleep-
related symptoms [84]. A recent study found duloxetine was 
an effective analgesic in patients with OA of the knee [90]. 
Corticosteroids 
 Due to their potent anti-inflammatory effects, 
corticosteroids have been shown to be effective adjuvant 
analgesics in a variety of painful rheumatic conditions, 
including RA and other autoimmune disorders [91]. 
Concerns about especially long-term toxicity [92], and 
adverse events may reduce the clinical utility of these agents 
for long-term care [23]. According to the NICE guidelines 
for RA, patients with established RA should only continue 
long-term treatment with glucocorticoids when the long-term 
complications of glucocorticoid therapy have been fully 
discussed, and all other treatment options (including 
biological drugs) have been offered [49]. Long-term 
complications of glucocorticoid therapy include 
glucocorticoid-induced osteoporosis and risk of fracture 
[93], immunosuppression [94], elevated risk of infections, 
weight gain, thinning skin, muscle weakness, Cushing’s 
syndrome, onset of diabetes or worsening of existing 
diabetes, hypertension, glaucoma, cataracts, and delayed 
wound healing [95]. 
Topical Agents 
 Topical products, such as lidocaine, diclofenac, 
capsaicin, and salicylate, allow the patient to obtain localized 
pain relief. They are mainly used in combination with 
systemic agents in the treatment of pain associated with 
rheumatic disease. Topical agents may be analgesic sparing 
in combination regimens [96]. Side effects include skin 
irritations, which are typically mild. Topical diclofenac has 
been reported to be effective in relieving pain caused by OA 
of the knee [97-99]. Topical 1% diclofenac sodium gel was 
shown to be an effective analgesic in a study of 385 primary 
hand OA patients, with about 9% of diclofenac patients 
experiencing adverse events (compared to 4% in placebo 
group) and 5% of diclofenac patients discontinuing therapy 
because of adverse events (2% in placebo group) [100]. In 
another study of 216 patients with OA of the knee treated 
with topical diclofenac to manage flares, diclofenac was 
effective in reducing pain but caused skin irritation in 39% 
of patients, with 5% choosing to discontinue therapy [101]. 
Topical NSAIDs do not appear to have gastrointestinal 
adverse effects typical of oral NSAIDs [102], but long-term 
studies are warranted to confirm this. OA treatment with 
topical lidocaine (5% lidocaine medicated plaster) as 
monotherapy or add-on therapy resulted in significant 
improvements in pain intensity [103-105], physical function, 
and stiffness [103]. The use of topical capsaicin in OA is 
discussed controversially: topical capsaicin is recommended 
for hand OA but not for knee OA according to the ACR 
guidelines (American College of Rheumatology) [106], 
whereas according to a recent review “concerns exist that 
capsaicin-induced nerve desensitization is not fully 
reversible and that its autonomic nerve effects may increase 
the risk of skin ulcers in diabetic patients” [107]. 
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COMBINATION THERAPIES 
 The multimechanistic nature of OA, RA and most other 
chronic pain indications suggests that a multimodal or  
combination approach to analgesia may be appropriate to 
manage pain. Combining two analgesic agents may allow for 
an additive or synergistic effect, which can affect both the  
drug’s analgesic efficacy as well as its side effect profile 
[108, 109]. Additive effects mean that the effects of both 
agents are combined. Synergistic effects result in a global 
effect that is greater than the sum of its parts. It is important 
to understand that additive and synergistic effects may imply 
side effects as well as efficacy. Furthermore, additive and 
synergistic effects may occur, yet fail to be clinically 
relevant. For these reasons, combination therapy holds 
promise in theory, but must be carefully evaluated and tested 
in actual clinical practice. 
 Fixed-dose combination analgesic products offer certain 
practical advantages, in that they are convenient, reduce the 
pill burden, and may allow for lower dosages that might be 
insufficient if the compounds were taken individually. Fixed-
dose combination analgesics should have complementary 
mechanisms of action and evidence supporting their safety 
and effectiveness. A drawback to fixed-dose combination 
analgesic products is inflexibility, in that the doses may not 
be ideal for the particular patient, and the fact that for 
continuous pain relief, generally a medication intake several 
times a day is required. 
 Paracetamol is often a component of combination 
products. A potential concern for such products is that they 
may obscure the patient’s cumulative dose of paracetamol 
(which should not exceed 4 g in healthy adults [110]). 
Typical combination products with paracetamol include 
opioid combinations (codeine, tramadol, oxycodone, etc.). 
These products may be opioid sparing, because they provide 
effective analgesia at lower opioid doses than opioids taken 
in monotherapy [111]. Synergistic analgesic benefits have 
been demonstrated for the fixed dose combination 
tramadol/paracetamol [112, 113]. 
 The Appendix lists all fixed-dose combination products 
with paracetamol that have been investigated for OA and RA 
pain treatment. They include paracetamol + strong opioids 
(oxycodone), + weak opioids (tramadol, codeine), and + 
NSAIDs (ibuprofen, etodolac, aceclofenac). 
PAIN CONTROL FOR OA AND RA PATIENTS 
 Paracetamol is effective in treating certain types of OA. 
The drug is considered as first-line treatment for mild to 
moderate pain [114]. However, OA patients often prefer 
NSAIDS for better pain relief [115]. NSAIDs are targeted 
therapy for pain management in RA patients, but are not 
appropriate for long-term disease control [49, 116-118]. 
 Fixed-dose combination products are seldom mentioned 
in available OA and RA guidelines [49, 50, 116-120]. The 
NICE guideline initially recommends paracetamol for all OA 
pain or topical NSAIDs for hand and knee OA ahead of oral 
NSAIDs, COX-2 inhibitors or opioids [50]. Topical 
capsaicin should be considered an adjunct to core treatment  
 
 
for hand and knee OA, and intra-articular corticosteroid 
injections an adjunct in all OA pain. The OARSI guideline 
recommends the initial administration of paracetamol for 
mild to moderate knee or hip OA, and topical NSAIDs and 
capsaicin as adjuncts or alternatives to oral analgesics in 
knee OA pain [119]. Weak opioids and narcotic analgesics 
can be considered for refractory pain but stronger opioids 
should only be used for severe pain in exceptional  
circumstances. The evidence presented included fixed-dose 
combinations of opioids and paracetamol. Both the NICE 
and OARSI guidelines recommend the use of oral NSAIDs 
at the lowest effective dose [50, 119]; long-term use should 
be avoided [119]. The recent ACR recommendations list 
topical capsaicin, topical NSAIDs, oral NSAIDs (including 
COX-2 inhibitors) and tramadol for initial pain treatment of 
hand OA, and advise against intra-articular therapies and 
opioid analgesics [106]. They recommend a similar approach 
for knee and hip OA which includes paracetamol, oral 
NSAIDs, tramadol, and intra-articular corticosteroid 
injections. Topical NSAIDs are recommended in knee OA 
(in particular for patients  75 years instead of oral NSAIDs) 
but there is no recommendation in hip OA. Topical capsaicin 
is not recommended in knee OA. Opioid analgesics are 
strongly recommended only in symptomatic knee or hip OA 
following insufficient response to both nonpharmacological 
and pharmacological treatments and where patients are not 
suitable for total joint arthroplasty. 
 Early use of DMARDs in RA patients is of high 
importance [121, 122] ; however, as pain is a major 
complaint in these patients, they commonly take analgesics 
from the very beginning. According to EULAR, 
symptomatic patients presenting with early arthritis should 
be treated with NSAIDs after careful evaluation of 
gastrointestinal, renal, and cardiovascular status [116]. The 
BSR guideline for long-term RA management recommends a 
stepped approach with NSAIDs co-prescribed with a proton 
pump inhibitor in the short term [117]. The NICE guideline 
suggests analgesics (for example paracetamol, codeine or 
compound analgesics [=fixed-dose combinations]) to 
potentially reduce the need for long-term NSAID or COX-2 
inhibitor treatment [49]. 
PANEL CONSIDERATIONS 
 The panel reached several general and specific 
conclusions on pain management for arthritis patients. While 
patient safety must be paramount, clinicians must address 
chronic pain associated with OA and RA. Not treating pain 
is not an option. Pain guidelines must offer clinicians better 
recommendations by taking into account the impact of pain 
as well as the multiple mechanisms of RA and OA pain. It is 
particularly important that clinicians realize that arthritis pain 
is not limited to nociception, but rather that non-nociceptive, 
neuropathic, and central mechanisms are also important 
components of OA and RA pain. 
 NSAIDs and paracetamol are commonly used, often 
recommended, and effective agents for the management of 
pain. However, they are not without potential risks, 
especially in the elderly and patients with renal,  
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gastrointestinal, or cardiovascular disease. High doses and 
long-duration use of NSAIDs to manage moderate to severe 
pain have been associated with tolerability issues and serious 
adverse events as well. Their role in the management of the 
chronic pain associated with OA and RA is thus limited. 
Higher doses of paracetamol have been associated with liver 
toxicity, and since paracetamol is a “hidden” ingredient in 
many over-the-counter products and other combination 
products, the hepatic injury is of particular concern. Fixed-
dose combination products including paracetamol may offer  
the drug and the combined agent in relatively low doses. 
Despite such lower-dose paracetamol treatment, patients 
should be educated in general about the dangers of 
paracetamol toxicity and cautioned about the amount of 
paracetamol contained in any combination products they 
may be prescribed. 
 Fixed-dose combinations of paracetamol provide a 
multimechanistic analgesic approach, which may be 
appropriate to address the pain of OA and RA. Fixed-dose 
weak opioid/paracetamol combination products have been 
shown to be effective in managing various types of moderate 
to severe pain, including the pain of OA and RA, with good 
tolerability. Tramadol, because of its opioid and nonopioid 
mechanisms of action, appears to be a promising opioid 
component in combinations for treating OA and RA pain. 
 Arthritis-related pain is generally characterized by flares 
of pain and periods of remission or relatively diminished 
pain. To manage long-term arthritis pain, a low-dose fixed-
dose combination product should be considered as the 
primary analgesic, providing safe and acceptable 
multimechanistic pain relief. NSAIDs should only be used to 
manage acute flares associated with inflammation. This is 
the reverse of a common treatment regimen in which patients 
take chronic NSAID therapy and use opioids to manage pain 
from flares. Potential advantages of using a low-dose opioid 
combination product include a broader analgesic spectrum, 
complementary pharmacokinetic profile, potentially 
synergistic analgesic benefits, and improved ratio of efficacy 
to adverse effects. 
CONCLUSION 
 Despite the wealth of analgesic options, treating arthritis-
related pain is still a challenge for clinicians balancing 
efficacy with safety aspects. Growing understanding of the 
multiple mechanisms of arthritis pain has given clinicians 
greater appreciation for a multimechanistic approach. The 
use of combination products, such as tramadol and 
paracetamol for long-term pain management, is a good 
option with proven evidence for relieving pain. NSAIDs are 
effective pain relievers and helpful as add-on treatment for 
the painful flares of arthritis. They are not safe at high doses 
or for long-term use, especially in the frail and elderly. 
Revised guidelines are required to help clinicians to better 
understand safe, effective treatment options for arthritis-
related pain. 
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APPENDIX 
Fixed-Dose Combination Therapies for Osteoarthritis and Rheumatoid Arthritis Pain. Only Combinations of 
Paracetamol with Other Analgesic Agents were Included. The List of Studies was Obtained Through PubMed Searches 
and Reference Lists of Pain Review Articles 
 
Study N Agent(s) Comparator Results Comments 
Strong Opioid/APAP Combinations 
Raffaeli 2010 [123] 
29 RA patients with 
chronic moderate to 
severe pain, not 
taking biologics 
Oxycodone/APAP 
started at 5/325 mg and 
titrated to attainment of 
good pain relief 
None 
42% had good clinical 
response (EULAR) 
and 50% showed 20% 
improvement. Mean 
daily dose at end of 
study was 13.8 (±6.8) 
mg/720.4 (±291.0) mg  
Mild to moderate nausea and 
vomiting; no serious AEs. 
Patients were allowed 
antiemetic drugs and 
laxatives as needed. 
Corsinovi 2009 [124] 
154 women nursing 
home residents with 
moderate to severe 
OA pain 
Oxycodone/APAP 
(average dose 16/900 
mg) and codeine/APAP 
(average dose 115/1916 
mg) 
Conventional 
therapy (NSAIDs, 
APAP, COX-2 
inhibitors) 
Oxycodone/APAP and 
codeine/APAP 
significantly reduced 
mean pain at six weeks 
versus conventional 
therapy (p<0.001 and 
p=0.004, respectively) 
AEs did not differ 
significantly among groups. 
Patients were all elderly 
females. 
Weak Opioid/APAP Combinations 
Mullican 2001 [125]  
462 patients with OA 
or LBP 
Tramadol/APAP 
(37.5/325 mg) 
(average dose 131/1133 
mg) 
Codeine/APAP 
(30/300 mg) 
(average dose 
105/1054 mg) 
Tramadol/APAP was 
as effective as 
codeine/APAP and 
better tolerated 
Codeine patients had 
significantly higher rates of 
somnolence and constipation, 
while tramadol patients had 
higher rate of headache (NS) 
Palangio 2000 [126] 
469 chronic pain 
patients (31% had 
arthritis, n=145) 
1 tablet of 
hydrocodone/ibuprofen 
7.5/200 mg daily (HI-1) 
or 2 tablets of same (HI-
2) 
Codeine/APAP 
30/300 mg 
HI-2 offered 
significantly greater 
pain relief than HI-1 or 
comparator; no 
efficacy differences 
between HI-1 and 
comparator 
No significant difference in 
AEs by group (83% HI-2, 
80% HI-1, and 81% 
Comparator) but significantly 
more HI-2 patients 
discontinued therapy due to 
adverse events compared to 
HI-1 (26% vs 15%, p=0.013) 
Conaghan 2011 [127] 
220 patients with hip 
and/or knee pain 
60 years of age 
7-day buprenorphine 
patches (range 5-25 
g/h) + APAP 1000 mg 
qid 
Codeine/APAP 
range 16 mg/1000 
mg qid to 60 
mg/1000 mg qid 
Non-inferiority of 
patch+APAP to 
codeine/APAP 
combination regarding 
analgesic efficacy 
Comparable incidence 
of AEs 
High withdrawal rates in 
both groups 
Emkey 2004 [128] 
306 OA patients 
taking a COX-2 
inhibitor 
Tramadol/APAP 
(37.5/325 mg) as add-on 
(average dose 154/1332 
mg) 
Placebo as add-on 
Tramadol/APAP 
patients had 
significantly better 
scores on VAS, pain 
relief and function; 
13% of tramadol and 
4% of placebo patients 
discontinued because 
of AEs 
 
Park 2011 [129] 
97 knee OA patients 
in sub-study (part of 
larger study, n=112) 
Tramadol/APAP 
(37.5/325 mg) Mean 
dose 3.23 tablets/day 
NSAID 
No significant 
differences in 
analgesia or AEs 
 
Alwine 2000 [130] 
403 patients with OA 
or low back pain 
Tramadol/APAP (37.5 
mg/325 mg) 1 to 3 
tablets per day  
4-week active 
control, thereafter 
open label (24 m) 
Tramadol/APAP rated 
“excellent” or “very 
good” by 39% of 
patients and 40% of 
investigators, average 
daily dose was 157 
mg/1363 mg.  
24% of patients discontinued 
due to AEs 
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